Janus Henderson Group
VRNA

Janus Henderson Group’s Verona Pharma VRNA Stock Holding History

Janus Henderson Group’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,010,564
Closed -$108M – 2476
2025
Q3 		$108M Sell
1,010,564
-5,123,841
-84% -$535M 0.05% 268
2025
Q2 		$580M Buy
6,134,405
+617,516
+11% +$45.7M 0.28% 75
2025
Q1 		$346M Buy
5,516,889
+3,849,724
+231% +$230M 0.19% 126
2024
Q4 		$77.5M Buy
1,667,165
+624,370
+60% +$23.4M 0.04% 305
2024
Q3 		$30M Sell
1,042,795
-49,247
-5% -$1.21M 0.02% 497
2024
Q2 		$15.8M Sell
1,092,042
-939,952
-46% -$13.7M 0.01% 617
2024
Q1 		$32.7M Buy
2,031,994
+228,633
+13% +$3.95M 0.02% 465
2023
Q4 		$35.8M Buy
1,803,361
+166,539
+10% +$2.46M 0.02% 436
2023
Q3 		$26.7M Buy
1,636,822
+1,212,266
+286% +$23.3M 0.02% 479
2023
Q2 		$8.97M Buy
424,556
+201,527
+90% +$4.3M 0.01% 705
2023
Q1 		$4.48M Sell
223,029
-315,605
-59% -$6.81M ﹤0.01% 908
2022
Q4 		$14.1M Sell
538,634
-61,366
-10% -$817K 0.01% 641
2022
Q3 		$6.14M Buy
+600,000
New +$5.06M ﹤0.01% 944

Other funds holding VRNA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Janus Henderson Group's VRNA Position: Q4 2025 in Review

Janus Henderson Group sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,010,564 shares — an estimated $108M sold.

Janus Henderson Group first reported a position in VRNA in Q3 2022 and held it in 13 quarters. The position peaked at $580M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • Janus Henderson Group reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • Janus Henderson Group sold 1,010,564 Verona Pharma shares in Q4 2025, an estimated $108M.
  • Janus Henderson Group first reported a position in Verona Pharma in Q3 2022 and held it in 13 quarters.
  • Janus Henderson Group's Verona Pharma position peaked at $580M in Q2 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Janus Henderson Group's 13F filing for Q4 2025, filed 17 Feb 2026.